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Methods and Patients: Patients with NSCLC and proven ipsilateral or 
subcarinal lymph node metastases (N2 disease, 3A disease stage) who 
had been treated with induction chemotherapy and showing at least 
stable disease or partial response on CT imaging underwent mediastinal 
restaging by EBUS-TBNA. This was followed by surgical resection of 
the tumour with lymph node dissection. 
Results: 124 Patients (51 male, 73 female, mean age 58 y.) had either 
a partial response (n=66) or stable disease (n=58) based on sequential 
CT scans of the thorax. After restaging all patients underwent surgery. 
Overall the sensitivity, speciﬁcity, positive predictive value, negative 
predictive value and diagnostic accuracy of EBUS-TBNA for medias-
tinal re-staging following induction chemotherapy were 76%, 100%, 
100%, 20% and 77% respectively. 
Conclusions: EBUS-TBNA is an accurate, safe and minimally invasive 
diagnostic technique for the restaging of mediastinal lymph nodes after 
induction therapy in NSCLC. It’s routine use for this purpose should be 
considered.
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Background: CT-guided Transthoracic Needle Biopsy (TNB) is 
commonly used in the diagnosis of thoracic lesions. PNX is the most 
common complication of this procedure with a reported rate from 8 
to 61%, with few cases requiring chest tube insertion. The aim of this 
prospective study was to estimate the risk of PNX in patients undergo-
ing CT-guided lung biopsy and to determine which factors affect its 
occurrence. 
Methods: Between November 2002 and August 2006, 708 TNB were 
performed in 691 patients with a CT-documented central or peripheral 
pulmonary lesion: 75% were males, median age was 67 years (range 
29-87). Risk factors for PNX were classiﬁed in three groups: patient-
related (age, sex, emphysema around the lesion), lesion-related (size, 
depth, location, presence of cavitations and/or pleural tags, chest wall 
invasion, pleural thickening, ﬁssure/atelectasis in the needle path) 
and procedure-related (patient position, needle puncture side, chest 
wall thickness, dwell-time (time between pleural puncture and needle 
removal), needle-pleural angle (smallest angle of the needle with the 
pleura), number of cutting specimens, number of pleural passages. 
Lesion depth was measured as the length of the aerated lung from the 
surface of pleura to the edge of the lesion. Lesion size was considered 
the average lesion diameter in two axial planes. Immediately after 
the procedure, a CT scan was obtained to control presence of PNX; 
patients were followed-up for 4 hours and chest radiographs were 
obtained at the end of this period. All variables were analysed by Chi-
square and Student t test for occurrence of PNX and p value < 0.05 was 
considered as statistically signiﬁcant. 
Results: PNX occurred in 181/708 procedures (25.6%) and tube 
insertion was required in 18 cases (2.5%). An higher lesion depth was 
the most signiﬁcant predictor of PNX (p=0.002): the mean depth of 
lesions from the pleural surface was 27.4 mm in patients with PNX 
and 17.2 mm in patients without PNX. There were 216 lesions in direct 
contact with the pleura: PNX developed in only 20 (9.2%). Among 
lesion related variables, chest wall invasion (p<0.03) and lesion size 
(p=0.03; 31.7 mm in group with vs 38.9 mm in group without PNX) 
showed correlation. A greater incidence of PNX was seen in smaller 
lesions: for lesions 1 cm or smaller, the rate was 35%. Among patient 
and procedure variables, age (68 vs 64 years, p<0.03) and number of 
cutting specimens (p=0.01) were associated with an increased risk of 
PNX. Number of pleural punctures, needle-pleural angle, dwell-time, 
lesion location, presence of emphysema along needle path and sex did 
not effect risk of PNX. 
Conclusion: In consecutive cases of CT-guided TNB the length of the 
lung parenchyma crossed during the biopsy is the predominant risk fac-
tor for PNX. The risk of PNX was also related to the mean lesion size, 
age, presence of chest wall invasion and number of cutting specimens.
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Accurate staging allows assessment of prognosis and determines 
treatment plans in patients with lung cancer. Evaluation of mediastinal 
lymphnodes (LN) is crucial to determine the stage of the cancer. Only 
up to 20% of patients with lung cancer present in early stage allow-
ing surgical treatment. Current mediastinal staging methods include 
mediastinoscopy (MS) and CT-PET. MS with the sensitivity of 70% 
- 95% is the gold standard in evaluation of LN and provides access to 
LN stations: 2, 3, 4, and 7. MS is an invasive procedure, which requires 
general anaesthetic, carries minimal, nonetheless, mortality and for 
technical reasons it is usually done only once. There is therefore a need 
to develop less invasive techniques allowing an adequate evaluation 
of mediastinal LN. CT-PET has been shown to be useful in predicting 
malignant mediastinal LN with a high negative predictive value (97%) 
but with only moderate positive predictive value (75%). However, 
CT-PET does not provide histological diagnosis. Real-time Endobron-
chial Ultrasound FNA with Doppler facilities (EBUS) provides a safe 
alternative to MS in staging of lung cancer. EBUS allows easy access 
to mediastinal and hilar LN stations: 2, 3, 4, 7, 10 and 11. EBUS is 
performed as an out-patient procedure in conjunction with standard 
bronchoscopy under conscious sedation.
We have performed 300 EBUS procedures from May 2005 until Mar 
2007 using an OLYMPUS Ultrasonic Linear Bronchoscope BF-UM40. 
Tissue samples were obtained using 22G needle and processed using a 
thin layer technique and stained with PAP. Any residual material was 
processed as a cell block.
There were 153 positive aspirations for malignancy. In 124 cases we 
diagnosed Non Small Cell Lung Cancer, 23 Small Cell Lung Cancer 
and 6 mixed tumours. The most frequently (in order) sampled LN sta-
tions were: 7, 4, 10, 11, 2 and 3. There were 7 false negative results. 
87 primary tissue diagnoses were obtained and 137 MS were avoided. 
There were no complications. Calculated EBUS sensitivity was 94% 
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with accuracy 96%. 19 patients with N2 negative EBUS pathology 
went on to have further staging with MS. Four of those patients proved 
to be N2 positive on mediastinoscopy. Two of these patients had N2 
negative CT-PET. 
In conclusion, EBUS in conjunction with CT -PET should be consid-
ered as a safe and effective alternative for MS in the staging algorithm 
in lung cancer. It is estimated that approximately 70% of MS could be 
avoided when EBUS is fully established. We believe that EBUS is a 
highly sensitive tool in staging of lung cancer and that it may offer a 
useful role in the re-staging of patients with lung cancer (stage IIIA) 
after neo-adjuvant therapy. Moreover, careful evaluation of mediastinal 
and hilar LN with EBUS provides very accurate, non-invasive staging 
in lung cancer thus assists planning the radical but non-surgical treat-
ment with chemo-radiotherapy.
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Objective: To determine the ability of endobronchial, ultrasound-guid-
ed ﬁne needle aspira-tion (EBUS-FNA) to successfully biopsy centrally 
located lung tumours in patients for whom conventional bronchoscopy 
has been non-diagnostic 
Methods: Patients (n = 110) with suspected lung cancer and an intra-
pulmonary tumour lo-cated near or adjacent to the central part of the 
bronchial tree, or with suspected metastases to the mediastinum or to 
the hilar lymph nodes, and who had undergone a non-diagnostic bron-
choscopy, underwent EBUS-FNA. Diagnoses based on EBUS-FNA 
biopsies were veriﬁed by mediastinoscopy or EUS FNA and if these 
procedures was non-diagnostic during surgical resection if the biopsy 
indicated non-small-cell lung cancer 
Results: EBUS-FNA biopsies established a speciﬁc diagnosis in 103 of 
110 patients (97%) and a diagnosis of lung cancer in 82 patients (72%). 
No complications occurred. The diagnoses made possible by EBUS-
FNA were conﬁrmed in all patients by mediastinoscopy, EUS FNA or 
thoracotomy. In 17 patients the malignant diagnose was obtained by 
puncture of N1 Lymph Nodes.
In 7 patients in whom EBUS-FNA was non-diagnostic because the cell 
types were not representative of this disease, a diagnosis was estab-
lished at surgery. 
Conclusions: EBUS-FNA qualiﬁes as the next diagnostic step in 
patients with suspected lung cancer, if conventional bronchoscopy is 
non-diagnostic and when the intrapulmonary mass is located adjacent 
to or near the central parts of the bronchial tree or in whom metastases 
to the mediastinum or hilar lymph nodes is suspected. In these cases, 
EBUS-FNA may decrease the number of required mediastinoscopies 
and exploratory thoracotomies
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Background: Mediastinoscopy has been a gold standard for mediasti-
nal staging of non-small cell lung cancer. We questioned that medias-
tinoscopy is still necessary as a staging tool for T1N0 NSCLC on both 
CT and PET/CT.
Methods: We conducted a retrospective review of 284 consecutive 
patients with T1N0 on both CT and PET/CT scan between July 2003 
and December 2006. All patients were surgically examined for medi-
astinal node by mediastinoscopy (n=145) or direct curative pulmonary 
resection and complete mediastinal node dissection (n=139). Neoadju-
vant therapy was planned for mediatinoscopy-positive patients (n=6) 
and pulmonary resection were performed for mediatinoscopy-negative 
patients (n=139).
Results: Median patient age was 60 years (23-81 years), and 59% were 
male (n=168). Cell types of lung cancer pathology included adeno-
carcinoma (n=201), bronchioloalveolar caricinoma(n=20), squamous 
carcinoma (n=44), large cell carcinoma(n=6), and others(n=13). Fifteen 
patients showed pathological N2 disease, therefore false negative rate 
of CT and PET/CT imaging was 5.3% (15/284). They had all pathology 
of adenocarcinoma. N2 disease was found in two patients (1 paratra-
cheal and 1 subcarinal node) among 139 patients who underwent resec-
tion without mediastinoscopy. False negative rate of imaging combined 
with mediastinoscopy was 5.0% (7/139); 7 patients had N2 among 139 
patients who underwent resection following mediastinoscopy-negative 
result (3 paratracheal/subcarinal, 3 subaortic, and 1 inferior pulmonary 
ligament LN).
Conclusions: CT and PET/CT scan provided satisfactory value of 
negative predictive rate of mediastinal node staging in T1N0 NSCLC. 
Further evaluation by mediastinoscopy in T1N0 on CT & PET/CT was 
not helpful due to limitation to examine subaortic and lower mediasti-
nal nodes and its inherent procedural errors. In conclusion, mediasti-
noscopy is not recommendable for staging tool of T1N0 NSCLC on CT 
and PET/CT.
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